Abstract. Background/Aim: Methotrexate (MTX)-associated classical Hodgkin lymphoma (CHL) is a rare disease, and its prognosis remains unclear. Materials and Methods: Our study retrospectively compared clinicopathological features and clinical outcomes of patients with MTX-CHL (n=6) and sporadic CHL (n=40). Results: MTX-CHL was more frequently the mixed cellularity subtype and positive for Epstein–Barr virus, but less frequently positive for CD20 than sporadic CHL. Clinically, MTX-CHL was more frequent in advanced stage than sporadic CHL and often associated with extranodal disease. After the cessation of MTX, transient spontaneous regression was observed in two MTX-CHL cases. Eventually, all patients with MTX-CHL required chemotherapy, which gave similar complete remission rates at 2 years compared to sporadic CHL. Patients with MTX-CHL tended to have a higher incidence of grade 3 or more neutropenia. Conclusion: The present study revealed differences in clinicopathological features but similarities in clinical outcomes of MTX-CHL and sporadic CHL.

Other iatrogenic immunodeficiency-associated lymphoproliferative disorders (LPDs) typically develop in patients with autoimmune diseases who are receiving methotrexate (MTX) and other biological immunosuppressive drugs (1). MTX was the first anticancer/immunosuppressive drug to be associated with LPDs (2, 3). LPDs in patients treated with MTX are defined as MTX-associated LPDs (MTX-LPDs). MTX-LPDs exhibit various histopathological features. The most common subtype is diffuse large B-cell lymphoma (DLBCL), while classical Hodgkin’s lymphoma (CHL) type accounts for 12-25% of all MTX-LPDs (1). It has been reported that approximately 80% of patients with MTX-DLBCL exhibit remission after MTX discontinuation alone and need no additional chemotherapy (4). Furthermore, other studies have found that patients with MTX-DLBCL who need additional chemotherapy because of disease progression have a better prognosis than those with sporadic DLBCL after receiving rituximab-containing chemotherapy (5, 6).

In contrast, the majority of patients with MTX-CHL require additional chemotherapy (1, 4, 7, 8); their prognosis remains unclear because of the rarity of MTX-CHL. To order to elucidate the differences between MTX-CHL and sporadic CHL, we retrospectively analyzed and compared the clinicopathological features and clinical outcomes of such cases at our Institution.

Materials and Methods

Patients. This study retrospectively analyzed patients with newly diagnosed CHL who were treated at the Tokyo Medical and Dental University Hospital between March 1995 and June 2016. Institutional Review Board approval was obtained (M2017-086). All patients were diagnosed via biopsy of the primary lesion. No patient had previously received chemotherapy for other malignancies. Cases pathologically diagnosed as CHL during continued MTX therapy were defined as MTX-CHL. The staging and response were defined following the Lugano Criteria (9).

Statistical analysis. Clinicopathological differences between patients with sporadic CHL and those with MTX-CHL were compared using Student’s t- and chi-square tests. Overall survival (OS) was defined as the time from the date of starting chemotherapy to the date of death from any cause or censored at the date of last contact. Progression-free survival (PFS) was defined as the time from the date of starting chemotherapy to date of relapse or death. The Kaplan-Meier method was used to estimate OS and PFS. Differences in survival between the two groups were analyzed by
the log-rank test. All reported *p*-values were two-sided, and values of *p*<0.05 were considered significant. All analyses were carried out with EZR software (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical computing) (10).

### Results

**Clinical background and treatment of MTX-CHL.** Forty-six patients were diagnosed with CHL during the study period, with six defined as having MTX-CHL. The clinical features of MTX-CHL are shown in Table I. The median age at diagnosis was 58 years (range=48-72 years). There were four females and two males. The indications for MTX treatment were rheumatoid arthritis (RA) in four, RA with Sjogren syndrome in one, and psoriatic arthritis in one. The median duration of MTX treatment was 6 years (range=5-13 years). Four patients also received biological immunomodulatory agents. All patients had bilateral diaphragmatic involvement, and three out of the six had extranodal lesions in the bone or lungs. MTX was discontinued immediately after MTX-CHL was diagnosed. After cessation, four patients showed no regression and two showed only transient regression. In the two patients who showed transient regression, the absolute lymphocyte count (ALC) was lower than 500/μl at the time of MTX-CHL diagnosis, which then increased after MTX cessation. However, ALC decreased again with the relapse of CHL. Conversely, the C-reactive protein (CRP) level was elevated at the time of diagnosis, decreased after MTX cessation, and increased again at relapse.

All patients except one were positive for Epstein–Barr virus-encoded small RNA (EBER), and all received induction therapy with doxorubicin, bleomycin, vincristine, and dacarbazine (ABVD) at a median of 2.5 months after MTX cessation. Five out of the six patients achieved complete remission (CR). The remaining patient whose treatment response was stable disease after two cycles of ABVD was converted to escalated therapy with bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone [dose-escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)]; CR was achieved after four cycles.

**Comparison of the clinicopathological features between patients with MTX-CHL and sporadic CHL.** Patient characteristics of both groups are shown in Table II. Median age was 58 years for the MTX-CHL group (n=6) and 45 years in the sporadic CHL group (n=40). Histopathologically, the percentage of patients with mixed cellularity subtype of CHL was significantly higher in the MTX-CHL group than

---

**Table I. Clinical background and treatment of methotrexate (MTX)-associated classical Hodgkin lymphoma.**

| Age, years | 71 | 55 | 48 | 72 | 58 | 57 |
| Gender | Female | Female | Male | Female | Female | Male |
| Pathology | MC | MC | MC | MC | MC | ND |
| Primary disease | RA | RA | RA | RA/SS | RA | PA |
| Duration of MTX (years) | 6 | 13 | 6 | 6 | 6 | 5 |
| Other immunotherapies | BUC, ETN, | SASP | PSL, BUC, | BUC, SASP, | BUC, PSL, | IFX |
| Involved site | C, A, M, H, P*, I Bone | C*, M, H, P Lung | C*, A, M, H, P Bone | C*, M, H, P*, Spleen Bone | C*, M, S Bone | W*, C, P |
| WBC (n/μl)/ALC (n/μl)/CRP (mg/dl) | | | | | | |
| At diagnosis | 3200/460/10.81 | 3700/359/5.4 | 13900/902/8.24 | 2400/902/0.05 | 6200/1910/0.47 | 7000/1400/0.15 |
| 2 Weeks after MTX cessation | 3800/1322/0.36 | 7200/1872/0.32 | 11300/1356/4.2 | 2900/1131/0.13 | 4900/1078/1.67 | 7700/2618/0.06 |
| Regrowth | 5900/236/8.29 | 8100/810/6.58 | - | - | - | - |
| EBER | + | + | + | + | + | - |
| Response | | | | | | |
| After MTX withdrawal | Regression -> | Regression -> | No change | No change | No change | - |
| (13 months) | regrowth | regrowth | (30 months) | | | |
| After ABVD chemotherapy | CR | CR | CR | CR | CR | SD |

MC: Mixed cellularity, ND: not determined; ALC: absolute lymphocyte count; RA: rheumatoid arthritis; SS: Sjogren syndrome; PA: psoriatic arthritis; BUC: bucilamin; ETN: etanercept; PSL: prednisolone; C: cervical; A: axillary; M: mediastinal; H: hilar; P: para-aortic; I: iliac; S: spleen; W: Waldeyer’s ring; EBER: Epstein–Barr virus-encoded small RNA; IFX: infliximab, SASP: salazosulfapyridine, ADA: adalimumab, ABVD: doxorubicin, bleomycin, vincristine and procarbazine *Biopsy site.
Table II. Differences of clinicopathological characteristics between patients with methotrexate (MTX)-associated classical Hodgkin lymphoma (CHL) and sporadic CHL.

|                    | MTX-CHL (n=6) | Sporadic CHL (n=40) | p-Value |
|--------------------|---------------|----------------------|---------|
| Age (median)       | 58 (48-72)    | 45 (17-83)           | 0.119   |
| Gender n (%)       |               |                      |         |
| Male               | 2 (33%)       | 23 (58%)             | 0.504   |
| Female             | 4 (66%)       | 17 (43%)             |         |
| Pathology n (%)    |               |                      |         |
| Nodular sclerosis  | 0             | 16/38 (42%)          | 0.040   |
| Mixed cellularity  | 5/5 (100%)    | 16/38 (42%)          |         |
| Other              | 0/6 (0%)      | 10/26 (38%)          |         |
| CD30 positive n (%)| 6/6 (100%)    | 26/26 (100%)         |         |
| CD20 positive n (%)| 0/6 (0%)      | 10/26 (38%)          | 0.023   |
| EBER positive n (%)| 5/6 (83%)     | 9/20 (45%)           | 0.008   |
| Ann Arbor stage (stage IIII-IV) | 6 (100%) | 19 (48%) | 0.049 |
| B Symptoms         | 2 (33%)       | 11 (28%)             | 1       |
| Bulky mass         | 0 (0%)        | 7 (18%)              | 0.615   |
| Extranol site      | 3 (50%)       | 11 (28%)             | 0.521   |
| Bone marrow        | 0             | 3                    |         |
| Lang               | 1             | 4                    |         |
| Bone               | 2             | 4                    |         |
| Other              |               |                      |         |
| Median WBC (n/μl)  | 4950 (2400-13900) | 7150 (2300-24300) | 0.174   |
| Median ALC (n/μl)  | 1151 (359-1910) | 1200 (174-3040)     | 0.479   |
| Median LDH (U/l)   | 249 (180-350)  | 235 (150-750)        | 0.707   |
| Median CRP (mg/dl) | 2.94 (0.05-10.81) | 2.4 (0-18.47)      | 0.739   |
| Median sIL2R (U/ml)| 1735 (812-3500) | 1350 (267-10200)    | 0.754   |
| GHSG (early-stage) | -             | 12/9                 |         |
| IPS (advanced-stage) | 5/1       | 12/7                | 0.673   |
| CR after induction therapy, n (%) | 5/6 (83%) | 35/38 (92%) | >0.99   |

EBER: Epstein-Bar virus-encoded small RNA; WBC: white blood count; ALC: absolute lymphocyte count; sIL2R: soluble interleukin-2 receptor LDH: lactate dehydrogenase; CRP: C-reactive protein; GHSG: German Hodgkin Study Group; IPS: International Prognostic Score; CR: complete remission.

The CR rates after induction therapy were not different between the MTX-CHL and sporadic CHL groups (83% vs. 92%, p=0.99). Four patients whose responses were less than partial remission received salvage therapy (three chemotherapy, one radiotherapy), and three out of these four responded (two CRs, one partial), including one patient with MTX-CHL. Adverse events, postponement, and dose reduction of ABVD. Adverse events (AE) of induction therapy are shown in Table III. The incidence of grade 3 neutropenia tended to be higher in the MTX-CHL group than the group with sporadic CHL (100% vs. 57%, p=0.13). There were no differences between the two groups in non-hematological AEs. We also evaluated postponement and dose reduction of ABVD therapy. The median cycle duration tended to be longer in the MTX-CHL group than the sporadic CHL group (35 vs. 28 days, respectively, p=0.44), and dose reductions were more common in the MTX-CHL group than the sporadic CHL group (80% vs. 29%, respectively, p=0.05).

Survival. The median follow-up was 48 months (range=8-66 months) in the MTX-CHL group and 64 months (range=1-258 months) in the sporadic CHL group. PFS and OS are shown in Figure 1. There were no significant differences between the MTX-CHL and sporadic CHL groups in 2-year PFS (83.3% vs. 72.8%, p=0.81) or 2-year OS (100% vs. 94.3%, p=0.43).
Discussion

The present study revealed that a significantly higher proportion of cases of MTX-CHL were of the mixed cellularity subtype and EBER-positive compared to sporadic CHL, while the rate of CD20-positive cases in MTX-CHL was significantly lower. Although there have been few studies reporting the subtypes of MTX-CHL, Loo et al. reported that 61% of CHLs arising in patients with autoimmune diseases were the mixed cellularity subtype (7). In the present study, this subtype accounted for all the MTX-CHL cases in which the subtype could be determined (5/5), while 42% of sporadic cases showed this subtype in accordance with the generally reported rate of 20-25% (1). Thus, we consider that the mixed cellularity subtype is a typical although not defining characteristic of MTX-CHL. In this study, the proportion of EBER-positive cases of MTX-CHL was also high (83%), in agreement with previous reports (4, 7), and was significantly higher than that of sporadic CHL (45%). This high positive rate may be partly explained by the fact that 75% of mixed cellularity subtype CHLs have been reported to be EBER-positive (1); all the MTX-CHL cases in this study were mixed cellularity subtype. On the other hand, none of our MTX-CHL cases were positive for CD20, which is consistent with a previous study that reported only one CD20-positive case among 17 MTX-CHL cases (4). In contrast, 38% of our sporadic CHL cases were positive for CD20, which is comparable to previous reports (18-40%) (1, 11, 12). We found the difference between the groups to be statistically significant.

Although it is well established that more than 60% of patients with sporadic CHL have localized disease (1), all patients with MTX-CHL had advanced-stage CHL at the time of diagnosis in our study. Moreover, although extranodal disease is reported to be generally rare in sporadic CHL (1, 13), we identified it in 28% of our sporadic CHL cases. Fifty percent of patients with MTX-CHL had extranodal disease in our study, which is in agreement with previous studies that reported high rates of advanced-stage CHL and extranodal disease in 40-70% of patients with MTX-CHL (4, 7, 14). Therefore, high rates of advanced-stage CHL and extranodal disease are also typical clinical characteristics of MTX-CHL.

Table III. Adverse events, cycle duration and dose reduction of doxorubicin, bleomycin, vincristine, and dacarbazine in patients with methotrexate (MTX)-associated classical Hodgkin lymphoma (CHL) and sporadic CHL.

| Adverse events                     | MTX-CHL (n=5) | Sporadic CHL (n=21) | p-Value |
|------------------------------------|---------------|---------------------|---------|
| Neutropenia, grade ≥3              | 5 (100%)      | 12 (57%)            | 0.129   |
| Thrombocytopenia, grade ≥3         | 0             | 0                   |         |
| Liver dysfunction, grade ≥2        | 1 (20%)       | 1 (5%)              | 0.488   |
| Renal dysfunction, grade ≥2        | 0             | 0                   |         |
| Median cycle duration (range), days| 35 (28-42)    | 28 (28-42)          | 0.442   |
| Dose reduction, n (%)              | 4 (80%)       | 6 (29%)             | 0.055   |

Figure 1. Progression-free (A) and overall (B) survival of patients with methotrexate (MTX)-associated classical Hodgkin lymphoma (CHL) and sporadic CHL.
After the cessation of MTX, two out of six patients showed disease regression. The ALCs of both patients were lower than 500/μl at the time of diagnosis and increased rapidly 2 weeks after MTX was discontinued. A similar relationship between ALC recovery and disease regression has been reported (15, 16). MTX withdrawal resulted in immunological recovery and CR in 25-69% of patients with MTX-DLBCL (4, 14, 17). In contrast, almost all patients with MTX-CHL do not achieve remission nor immunological recovery (1, 4, 7, 8). In accordance with this, two patients in our study experienced a transient regression after ALC recovery, but both patients then experienced relapse. Disease relapse after transient regression has been reported in MTX-CHL (4, 14, 17), but the relationship between ALC and relapse has not been well-explained. Considering that the ALC decreased and the CRP level increased when the disease relapsed in both our patients, both might reflect disease activity and could possibly become promising markers for MTX-CHL in this regard.

All patients with MTX-CHL in this study eventually received ABVD chemotherapy because of residual disease or progression, with a response rate comparable to that of sporadic CHL. Previous studies have also reported that most MTX-CHL cases need chemotherapy and have a good response (4, 7, 8, 14). Concerning the AEs of ABVD, the incidence of grade 3 or more neutropenia tended to be higher and more patients required postponement or dose reduction in the MTX-CHL group, although these were not significantly different from those of the sporadic CHL group, most likely due to small sample size. The PFS and OS after initial treatment showed no difference between the two groups.

Although this study examined only six MTX-CHL patients, this is the first report that compared MTX-CHL with sporadic CHL with respect to clinicopathological features and treatment outcomes. Certain pathological features (mixed cellularity subtype, EBER positivity, CD20 negativity) and clinical features (advanced stage, extranodal disease) were proposed as important features of MTX-CHL. Moreover, recovery of ALC after MTX cessation correlated with and was implicated in transient regression of lymphoma. The present study further revealed that MTX-CHL did not differ from sporadic CHL in response to chemotherapy, PFS, or OS.

One unanswered question that remains regarding MTX-CHL is when to start chemotherapy. Our study demonstrated that patients with MTX-CHL eventually needed chemotherapy and suggested that timing of chemotherapy might not have affected the outcome. Considering the aggravation of autoimmune disease symptoms after the cessation of MTX, early intervention after diagnosis may be preferable in order to manage both the autoimmune disease and MTX-CHL. Another remaining question is the optimum chemotherapy regimen for these patients. A meta-analysis has shown the superior efficacy of BEACOPP over ABVD in the treatment of CHL (18). Moreover, brentuximab vedotin, doxorubicin and vincristine with dacarbazine (A-AVD) has recently been reported to show a better therapeutic effect than ABVD in advanced-stage CHL (19). The effectiveness of brentuximab vedotin for relapsed MTX-CHL has also been reported (20). Because the great majority of patients with MTX-CHL have advanced-stage disease, A-AVD may be more effective than ABVD for these patients. However, our study showed that patients with MTX-CHL showed more severe myelosuppression than two sporadic CHL. Myelosuppression is also reportedly more severe after A-AVD than ABVD (19). Therefore, it remains to be seen if A-AVD may be better than ABVD for MTX-CHL, and extra caution should be paid to myelosuppression during chemotherapy when A-AVD is used.

Conflicts of Interest

The Authors declare that they have no conflicts of interest in regard to this study.

Authors’ Contributions

Kota Yoshifuji: data collection, analysis and interpretation of results, statistical analyses, construction of a figure, editing and writing of the original article; Yoshihiro Umezawa: data collection and patient management; Ayako Ichikawa: data collection and interpretation of results, statistical analyses; Ken Watanabe: data collection and patient management; Osamu Miura: supervision of the project, critical revision of the article; Masahide Yamamoto: study design, data collection analysis and interpretation of results, statistical analyses, writing of article. All the Authors read and approved the final article.

References

1 Gaulard P, Swerdlow S, Harris N, Sundstrom C and Jaffe E: Other iatrogenic immunodeficiency-associated lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A and Siebert R: World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues. Revised Fourth Edition. Lyon: IARC: p. 462-464, 2017.

2 Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gómez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M and van der Heijde D: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76: 960-977, 2017. PMID: 28264816. DOI: 10.1136/annrheumdis-2016-210715
